Vladimir A Slesarev

US Patent:

7112564, Sep 26, 2006

Filed:

Apr 9, 2003

Appl. No.:

10/409846

Inventors:

Vladimir Ivanovich Slesarev - Boyds MD, US
Todor Vassilev Dimitrov - Chestnut Hill MA, US

Assignee:

Zylacta Corporation - Boyds MD

International Classification:

A61K 38/16

US Classification:

514 8

Abstract:

The endopeptidase hydrolysis of cross link peptide bond of the peptidoglycans results in release of the novel glucosaminemuramyl tri, tetra, penta, hexa, and octapeptides. Their structure is defined by specific endopeptidase cleavage as well as genus of gram positive bacteria. They are potent cytoprotective agents capable of inhibiting of TNF alpha cytotoxicity.

US Patent:

20040258779, Dec 23, 2004

Filed:

Jun 6, 2003

Appl. No.:

10/455123

Inventors:

Boris Pinegrin - Moscow, RU
Todor Dimitrov - Chestnut Hill MA, US
Vyacheslav Lvov - Moscow, RU
Vladimir Slesarev - Boyds MD, US
Musa Khaitov - Moscow, RU

International Classification:

A61K035/78

US Classification:

424/757000

Abstract:

A novel peptidoglycan compositions are offered for inhibition of apoptosis of hematopoietic cells. The active ingredient is N-acetyl-glucosamine-N-muramyl L-alanine-D-isoglutamine-meso-diaminopimelyl-D-alanine (GMTP). Its cytoprotective effect allows to treat leucopenia, anemia, and thrombocytopenia.

US Patent:

20060241025, Oct 26, 2006

Filed:

Jun 21, 2006

Appl. No.:

11/472059

Inventors:

Vladimir Slesarev - Boyds MD, US
Todor Dimitrov - Chestnut Hill MA, US

International Classification:

A61K 38/14
C07K 9/00

US Classification:

514008000, 530322000

Abstract:

The present invention includes apoptosis modulating glucosamine-muramyl-peptides, obtained by specific endopeptidase digestion of gram positive bacteria, methods of preparation of thereof and medical food compositions for management and treatment of conditions caused by TNF alpha cytotoxicity.